BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28464520)

  • 1. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m
    Blute ML; Kucherov V; Rushmer TJ; Damodaran S; Shi F; Abel EJ; Jarrard DF; Richards KA; Messing EM; Downs TM
    BJU Int; 2017 Sep; 120(3):387-393. PubMed ID: 28464520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence.
    Rausch S; Hennenlotter J; Todenhöfer T; Aufderklamm S; Schwentner C; Sievert KD; Stenzl A; Gakis G
    Urol Oncol; 2014 Nov; 32(8):1178-83. PubMed ID: 24962661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
    Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
    Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.
    Li CE; Chien CS; Chuang YC; Chang YI; Tang HP; Kang CH
    Int Urol Nephrol; 2016 Jun; 48(6):993-9. PubMed ID: 26995008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e1-684.e8. PubMed ID: 32201059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Kobatake K; Hayashi T; Black PC; Goto K; Sentani K; Kaneko M; Yasui W; Mita K; Teishima J; Matsubara A
    Int J Urol; 2017 Aug; 24(8):594-600. PubMed ID: 28734027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter?
    Ucpinar B; Erbin A; Ayranci A; Caglar U; Alis D; Basal S; Sarilar O; Akbulut MF
    J BUON; 2019; 24(4):1659-1665. PubMed ID: 31646822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer.
    Wu SC; Kwon D; Jue JS; Chen FV; Velasquez Escobar MC; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
    Eur Urol Focus; 2021 Jan; 7(1):142-147. PubMed ID: 31103602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
    Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
    BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes.
    Tseng CL; Lafrance JP; Lu SE; Soroka O; Miller DR; Maney M; Pogach LM
    BMC Nephrol; 2015 Mar; 16():34. PubMed ID: 25885708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer.
    Jancke G; Rosell J; Jahnson S
    Scand J Urol; 2014 Jun; 48(3):276-83. PubMed ID: 24286506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Areca Nut Chewing and an Impaired Estimated Glomerular Filtration Rate as Significant Risk Factors for Non-Muscle-Invasive Bladder Cancer Recurrence.
    Cao J; Xu R; Zhao X; Zhong Z; Zhang L; Zhu X; Wu S; Ai K
    Sci Rep; 2016 Jul; 6():29466. PubMed ID: 27385379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.
    von Landenberg N; Aziz A; von Rundstedt FC; Dobruch J; Kluth LA; Necchi A; Noon A; Rink M; Hendricksen K; Decaestecker KPJ; Seiler R; Poyet C; Fajkovic H; Shariat SF; Xylinas E; Roghmann F;
    Urol Oncol; 2018 May; 36(5):238.e19-238.e27. PubMed ID: 29506940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.
    Naito S; Algaba F; Babjuk M; Bryan RT; Sun YH; Valiquette L; de la Rosette J;
    Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
    Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
    BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?
    Ferrari P; Xiao J; Ukich A; Irish A
    Nephrol Dial Transplant; 2009 Jun; 24(6):1828-33. PubMed ID: 19131346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.
    Kohada Y; Hayashi T; Hsi RS; Yukihiro K; Sentani K; Goto K; Inoue S; Ohara S; Teishima J; Kajiwara M; Nishisaka T; Yasui W; Black PC; Matsubara A
    BJU Int; 2021 Apr; 127(4):473-485. PubMed ID: 32805763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.